Moleculin Biotech is trading at $5.85, up 10.38% at 9:43 a.m. ET on October 20, 2026, amid MIRACLE trial updates. - Part A enrollment is complete; full data are anticipated in Q1 2027. - The same-day CEO update covered trial progress and interim efficacy results; reports did not directly link the gain to these developments. - The 1-for-20 reverse split took effect before trading, reducing outstanding shares from about 20.9 million to approximately 1.05 million.